Home/Pipeline/Generic Portfolio Expansion - Anti-infectives

Generic Portfolio Expansion - Anti-infectives

Bacterial Infections

Regulatory SubmissionActiveN/A

Key Facts

Indication

Bacterial Infections

Phase

Regulatory Submission

Status

Active

Company

Alkaloid AD Skopje

About Alkaloid AD Skopje

Alkaloid's mission is to improve health and quality of life by providing high-quality, accessible pharmaceutical and consumer healthcare products. The company has achieved a dominant market position in Southeast Europe, established a resilient export business, and built a reputation for reliability over nearly nine decades. Its strategy is centered on leveraging its integrated operations, portfolio diversification, and regional distribution strength to drive sustainable growth in both domestic and international generic drug and consumer health markets.

View full company profile

Therapeutic Areas

Cardiovascular Central Nervous System Gastrointestinal Anti-infective Consumer Health

Other Bacterial Infections Drugs

Drug	Company	Phase	Status
Vibativ® (telavancin)	Cleo Life Sciences	Approved	Supported late-stage development & NDA
Penicillin V API	Biotika	Commercial	Active
Sterile Injectable Antibiotics Portfolio	Steripharma	Approved	Active
Oral Antibiotic	Dawah Pharmaceuticals	ANDA Filed/Pre-approval	Active
XAB05/XAB06	Xenothera	Preclinical	Active
Antibacterial Program	Prosetta Biosciences	Preclinical	Active
Novel Antibiotic Class 1	ArrePath	Pre-clinical	Active
Novel Antibiotic Class 2	ArrePath	Pre-clinical	Active
Amoxicillin/AmoxiClav Generics	Puren Pharmaceuticals	Approved	Active
Ready-to-Use Antibiotics in Bags	Galenica Senese	Commercial	Active
Lasvic (Lascufloxacin)	KYORIN Pharmaceutical	Marketed	Active
Anti-infective Candidate(s)	China Resources Pharmaceutical Group	Phase II / Phase III	Active